The Sanofi-backed cancer therapy developer is set to raise between $140m and $160m in its initial public offering following $226m in funding.
Revolution Medicines, a US-based precision oncology drug developer backed by pharmaceutical firm Sanofi, set terms yesterday for an initial public offering set to raise up to $160m.
The company set the range for the offering at $14 to $16 and plans to issue 10 million shares on the Nasdaq Global Market next week. JP Morgan Securities, Cowen and Company, SVB Leerink and Guggenheim Securities are joint book-running managers for the proposed IPO.
Founded in 2014, Revolution is working on…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
